Dermaxin Wrinkle Cream Promises Results Similar to Injectables
Posted by Cosmetic Surgery Review on November 29, 2009
Millions of men and women opt for dermal fillers and injectables such as Zyderm, Zyplast, Botox, Restylane and Juvederm to fill out lines and wrinkles, smooth out sagging skin and enhance their appearance.
The popularity of the ‘liquid facelift’ has encouraged many surgeons and aesthetic surgery professionals to sell more products that offer a quick fix for lines and wrinkles, and demand for brans including CosmoDerm, Dermalogen and Dysport has increased significantly over the past ten years.
Now, a wrinkle cream that has been deemed the world’s best topical collagen delivery system claims to offer results similar to injectables.
Dermaxin is the world’s leading anti-wrinkle cream, an all-natural collagen cream that penetrates deep into the skin within the first ten minutes after application. According to studies conducted by Dermaxin researchers, most people saw an overall reduction of wrinkles within the first 4 to 12 weeks of daily use (up to a 44% difference).
Since most injections cost between $500 to $1000 per series, Dermaxin offers a more affordable solution for getting rid of wrinkles, and does not require touchup treatments and appointments at a doctor’s office. Some people who are allergic to the toxic compounds in many injectables or those who experience burning and irritation at the injection site may be good candidates for a topical wrinkle treatment instead.
According to Dermaix spokesperson Teresa Richards, “Dermaxin uses is the most powerful delivery system in the world – Hyaluronic Acid – to penetrate the folds of the ski and supply collagen to the deep dermal layers…the same instantaneous wrinkle-busting and smoothing effect found with injections is also achieved –within the first ten minutes of using the product – thanks to the power of Acetyl Hexapeptide08, a proven facial-relaxing compound and wrinkle remover that provides results similar to those of Botox, but without any of the associated risks.” (Source: Dermaxin Press Release)